Wave Life Sciences (WVE) Soars Another 26% After Announcing Collaboration With GSK
Wave Life Sciences (WVE), rose another 26%, following yesterday’s 33% gain. The rise in value follows a lucrative collaboration with GSK.
Wave receives upfront payments of $170 million in cash and equity, and is also eligible to receive milestone payments and royalties. The collaboration brings together Wave’s PRISM oligonucleotide platform and GSK’s expertise in genetics and genomics.
Additionally, GSK receives exclusive global license to Wave’s prelicinical RNA editing program, WVE-006.
More details about the partnership can be found here.
WVE is a member of the PRISM Life Sciences Index, which is down for the day, at -0.8%. WVE led the pack with the Company’s 26% gain.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
